Kates R E, Keefe D L, Schwartz J, Harapat S, Kirsten E B, Harrison D C
Clin Pharmacol Ther. 1981 Jul;30(1):44-51. doi: 10.1038/clpt.1981.125.
Verapamil disposition was studied in 12 patients with chronic and fibrillation. After an intravenous bolus of 15 mg plasma concentration was determined and the data fit in a three-compartment model. Model independent parameters were calculated and values for half-life (t 1/2), clearance, and steady-state distribution volume were 6.3 +/- 4 hr, 13.3 +/- 7.7 ml/min/kg, and 4.3 +/- 1.9 l/kg. The model was used to design a multistep infusion scheme, which was employed successfully to achieve predetermined plasma concentrations. Following single oral doses of 120 mg, plasma levels of verapamil and norverapamil were determined. The elimination t 1/2 for verapamil and norverapamil were 8.3 +/- 6.1 and 10.5 +/- 5.6 hr, respectively. The bioavailability of oral verapamil was 35 +/- 16%. During long-term oral therapy the mean verapamil plasma concentration was twice the value predicted from the single-dose studies. This suggests that verapamil may have reduced clearance during long-term oral use.
对12例慢性房颤患者的维拉帕米处置情况进行了研究。静脉推注15毫克后,测定血浆浓度,并将数据拟合到三室模型中。计算了模型独立参数,半衰期(t 1/2)、清除率和稳态分布容积的值分别为6.3±4小时、13.3±7.7毫升/分钟/千克和4.3±1.9升/千克。该模型用于设计多步输注方案,该方案成功用于达到预定的血浆浓度。单次口服120毫克后,测定了维拉帕米和去甲维拉帕米的血浆水平。维拉帕米和去甲维拉帕米的消除t 1/2分别为8.3±6.1小时和10.5±5.6小时。口服维拉帕米的生物利用度为35±16%。在长期口服治疗期间,维拉帕米的平均血浆浓度是单剂量研究预测值的两倍。这表明维拉帕米在长期口服使用期间可能清除率降低。